Effect of Levosimendan on Estimated Glomerular Filtration Rate in Hospitalized Patients with Decompensated Heart Failure and Renal Dysfunction

Abstract

SUMMARYBackground: Only limited data of the long-term effect of levosimendan on renal dysfunction in patients with decompensated heart failure (DHF) have been published previously. To date, there has been no similar study carried out in a Chinese population. Design and Methods: A prospective, randomized, placebo-controlled, and double-blind study was performed to investigate the effect of levosimendan on estimated glomerular filtration rate (eGFR) in DHF patients with renal dysfunction during a 30-day period. Sixty-six patients with left ventricular ejection fraction (LVEF) 40% and eGFR 15-89 mL/min/1.73 m

The effects of levosimendan on renal function early after heart transplantation: results from a pilot randomized trial

“…In addition, LS may possess anti‐inflammatory and anti‐apoptotic properties that could protect against renal ischemia‐reperfusion injury . In accordance with our findings, several studies also support the reno‐protective effects of LS in different cardiac surgery settings .…”

Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations

“…In addition, intrarenal vasoconstriction mediated via the activation of multiple neurohormonal pathways may play a role in worsening renal function [62]. Beneficial effects of levosimendan on heart failure-related renal dysfunction have been recorded in several small studies [63][64][65][66]. Of note in the context of levosimendan therapy as a 'bridge' to successful heart transplantation, early postoperative use of levosimendan has been reported to improve renal function in transplant recipients [67].…”

The Cardiovascular Disease Risks of Nonthyroidal Illness Syndrome and Inflammatory Responses on Patients with Chronic Kidney Disease: From the Association to Clinical Prognosis

“…NTIS may lead to endothelial dysfunction, hypercoagulability, impaired fibrinolysis, hyperhomocysteinemia, systemic inflammation, and platelet abnormalities . Important changes in cardiac structure and function have been reported in patients with overt and subclinical hypothyroidism with a severity depending on the degree and duration of thyroid hormone declines . Given the potentially important role of FT3 and IL‐6 in CVD events, more extensive studies should be scheduled to elucidate the pathogenesis in patients with CKD.…”